Status:
UNKNOWN
Impact of Dose to Cardiac Substructures on Survival in Patients With Esophageal Cancer Treated With Radiotherapy or Chemoradiotherapy (SATIATION)
Lead Sponsor:
University Hospital, Brest
Conditions:
Esophagus Cancer
Eligibility:
All Genders
18+ years
Brief Summary
Treatment of non-operable esophageal cancers is based on radiochemotherapy, or exclusive radiotherapy. The cardiac toxicity of radiotherapy in the treatment of thoracic tumor localizations is well do...
Detailed Description
Treatment of non-operable esophageal cancers is based on radiochemotherapy, or exclusive radiotherapy. The cardiac toxicity of radiotherapy in the treatment of thoracic tumor localizations is well do...
Eligibility Criteria
Inclusion
- Age ≥ 18 years
- Histologically or cytologically proven esophageal cancer
- Localized or locally advanced esophageal cancer treated with radiochemotherapy or exclusive radiotherapy
- Tumor dose ≥ 50 Gy
- Non-opposition of living patients formulated
- Patient affiliated to a social security scheme
Exclusion
- Age \< 18 years
- Patient treated with upfront surgery
- Tumor dose \< 50 Gy
- Other concomitant neoplasia
- Metastatic patient
- Refusal to participate
- Patient under legal protection (guardianship, curatorship, etc...)
Key Trial Info
Start Date :
August 1 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 30 2024
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT05996276
Start Date
August 1 2023
End Date
September 30 2024
Last Update
August 9 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Chu Brest
Brest, France, 29609